Founders warned on regulatory timing

Health founders are being told to plan for Food and Drug Administration review and payment before they write product code, not after. (fda.gov) (x.com) That warning came in a recent X post from @thoughtson_tech, which argued that founders should map regulators, payers, providers, and buyers before building. A separate post from physician-investor Joshua Liu said clinicians who become founders often run into year-long pilots, slow hospital sales, and more than 130 investor rejections. (x.com 1) (x.com 2) In digital health, Food and Drug Administration clearance answers whether a tool can be marketed, while reimbursement answers who gets paid to use it. A company can solve the first problem and still fail on the second if Medicare, insurers, or health systems do not have a billing path or budget line. (fda.gov) (cms.gov) Federal agencies have been moving closer together on that gap. On December 9, 2025, the Food and Drug Administration said it would launch the Technology-Enabled Meaningful Patient Outcomes, or TEMPO, pilot with the Centers for Medicare & Medicaid Services Innovation Center to connect access, evidence, and payment for some digital health devices. (fda.gov) (federalregister.gov) Medicare already pays for some remote monitoring, but the rules are specific. The Centers for Medicare & Medicaid Services says remote patient monitoring has coverage and billing guidance, and the agency updated that page on March 4, 2026. (cms.gov) That leaves founders with a practical problem: a product has to fit clinical workflow, compliance rules, and payment mechanics at the same time. Liu’s list framed the issue from the operator’s side, describing long enterprise sales cycles and pilots that do not reliably convert into scaled contracts. (x.com) (cms.gov) Law firms and industry advisers have spent the past year parsing Medicare’s remote monitoring changes because small coding shifts can change whether a business model works. Analyses of the 2026 Medicare Physician Fee Schedule described new flexibility for remote patient monitoring and remote therapeutic monitoring, but also warned that compliance and documentation still drive payment. (foley.com) (mcguirewoods.com) The same pressure shows up in fundraising. If a startup cannot show who prescribes the product, who pays for it, and what evidence regulators or buyers will ask for, investors can treat the company as a science project instead of a business. (x.com) (fda.gov) The posts land as Washington is testing ways to tie digital tools more directly to measurable outcomes and payment. For founders, that turns regulatory timing from a late-stage checklist into an early design decision. (fda.gov) (federalregister.gov)